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Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is defined as fetal and neonatal 
thrombocytopenia caused by maternal alloantibodies directed against fetal platelets due to 
incompatibility between fetal and maternal platelet antigens (HPAs). The majority of FNAIT 
cases are caused by anti-HPA-1a antibodies(1). FNAIT is the most common cause of 
intracranial hemorrhage (ICH) in otherwise healthy term newborns, affecting 1:12,500 – 
1:25,000.The clinical outcome of FNAIT-related ICH is typically poor, and the risk of 
recurrence in subsequent pregnancies is high(2;3). FNAIT is also associated with increased 
risk of miscarriage, low birth weight, and stillbirth(1;4).  
Children with FNAIT are typically diagnosed unexpectedly and shortly after delivery. Current 
treatment protocols vary between countries, but most western countries offer antenatal IVIg 
given as weekly doses from 2nd trimester until delivery in pregnancies where the risk of 
FNAIT is known. IVIg treatment is considered effective when the neonatal platelet count 
in a subsequent pregnancy is increased compared with the previous FNAIT pregnancy. 
However, the natural course of FNAIT in several subsequent pregnancies was recently 
reported for the first time, questioning the effect of antenatal IVIG treatment on neonatal 
platelet counts(5). The effect of IVIg in preventing severe FNAIT regarding neonatal 
platelet count is therefore debatable, but it is generally agreed that IVIg reduces the risk of 
ICH recurrence from 70-80% risk without treatment to about 10% with IVIg(3). 
A Norwegian woman born 1979 had a child affected by severe FNAIT after her first 
pregnancy in 2002. At that time, she participated in a large Norwegian screening study(1) and 
was therefore identified already in the 1st trimester to have the rarer platelet antigen type 
HPA-1bb. She developed high levels of anti-HPA-1a antibodies targeting the fetus’ platelets 
at 24 weeks of pregnancy. The newborn had platelet count below 5 × 109/L and widespread 
skin bleedings at birth, and was transfused with compatible platelets shortly after delivery by 
cesarean section. She has since repeatedly tried to conceive with her HPA-1 discordant 
husband, but miscarried five pregnancies during the 1st trimester. We found a solution for this 
couple, which we believe could be a treatment option for other families in similar situation.  
After obtaining approval by the Norwegian Directorate of Health, we genotyped 50 open-
identity sperm donors and identified a donor with the compatible platelet antigen HPA-1bb. 
Our patient conceived after in vitro fertilization using sperm from the selected donor. She 
had an uneventful singleton pregnancy despite high and stable maternal serum levels of anti-
HPA-1a antibodies. No maternal anti-HLA class 1 antibodies were detected. A healthy 
newborn with normal platelet count (300 × 109/L) was delivered by elective cesarean section 
at 38 weeks of pregnancy. The patient described has given written approval of the 
content. 
 
We acknowledge the potential ethical challenges and concerns that this management option 
for FNAIT raise. It is important to consider if a woman has other alloantibody specificities in 
addition to anti-HPA-1a before undergoing this treatment, for example anti-HLA class 1 
antibodies. Nonetheless, we consider use of HPA-1-matched donor sperm as a safe and 
possible treatment for the minority of HPA-1bb women with history of recurrent devastating 
FNAIT-related complications, including ICH. The alternative choice for these couples would 
often be to refrain from further pregnancies.  
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